Patient-centered model aimed to improve healthcare through innovative medicines and therapies
The Soltero Cardiovascular Research Center began at Baylor Dallas in 1987 to bring clinically relevant cardiology research studies to Baylor Scott & White Health. The Center is improving patients' lives through innovative research to understand, prevent, and even reverse heart disease.
The Center is nationally recognized for conducting high-quality studies on cardiovascular problems, medications, and surgical procedures. Its studies have focused on cardiovascular problems caused by:
- Diabetes
- Hardening of arteries
- Alta presion sanguinea
- Increased levels of lipoprotein molecules in the blood
Soltero Cardiovascular Research Center is proud to be a MAGI Blue Ribbon Site
What it means to be a Blue Ribbon Site
Our mission
- Perform the highest quality clinical research
- Involve the Center in important practice-altering studies
- Facilitate high-quality care for our patients
- Promote innovative, creative, and original research
- Wisely use funds generated or generously donated
- Educate patients, Baylor Scott & White personnel, and our community on research concepts and results
Current research
-
Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis In the Treatment of Abdominal Aortic Aneurysms (EXCeL)
Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the treatment of abdominal aortic aneurysms.
-
Alirocumab in Patients on a Stable Dialysis Regimen (ALIDIAL)
A phase III trial to evaluate the efficacy and safety of biweekly alirocumab in patients on a stable dialysis regimen.
-
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)
A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with or at high risk for cardiovascular disease who are statin intolerant.
-
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. (DREAM HF-1)
A double-blind, randomized, sham-procedure-controlled, parallel-group efficacy and safety study of Allogeneic Mesenchymal Precursor Cells (rexlemesrocel-L) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or nonischemic etiology.
-
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
A phase III randomized, double-blind trial to evaluate the efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic heart failure with preserved ejection fraction (HFpEF).
-
Global Registry for Endovascular Aortic Treatment (GREAT)
A global registry for endovascular aortic treatment outcomes evaluation.
-
Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass (GUARD)
A multicenter, prospective, parallel-group, double-blind, randomized, placebo-controlled, phase II study of BB3 to assess the safety and efficacy of BB3 in patients developing acute kidney injury after cardiac surgery.
-
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)
An assessment of humacyte’s human acellular vessel in patients needing renal replacement therapy: A comparison with ePTFE grafts as conduits for hemodialysis.
-
On-X aortic valve replacement patients treated with low-dose warfarin and low-dose aspirin (On-X)
A longitudinal, randomized study comparing the On-X valve on low dose anticoagulation to concomitant control groups of On-X valves receiving standard Coumadin/aspirin therapy.
-
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI)
A multi-center, randomized, double-blind, active-controlled, parallel-group Phase III study to evaluate the efficacy and safety of LCZ696 (Entresto) compared to Ramipril on morbidity and mortality in high risk patients following an acute myocardial infection.
-
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction (PERSPECTIVE)
A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 (Entresto™) compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.
-
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery (QUARK 309)
A randomized, double-blind, placebo controlled, Phase III study to evaluate the efficacy and safety of QPI-1002 for the prevention of major adverse kidney events in subjects at high risk for acute kidney injury (AKI) following cardiac surgery.
-
SPYRAL PIVOTAL
SPYRAL HTN-OFF MED - A multi-center, prospective, single blinded, 1:1 randomized, sham-procedure controlled global clinical study of renal denervation with the Symplicity Spyral™ multi-electrode renal denervation system in patients with uncontrolled hypertension in the absence of antihypertensive medication.
-
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
A multi-center, prospective, single blinded, 2:1 (treatment to control) randomized, sham-procedure controlled global clinical study of renal denervation with the Symplicity Spyral™ multi-electrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy.
Investigators
Physician leadership
Cara East
Medical Director, Soltero Cardiovascular Research Center; Clinical Professor, Texas A&M College of Medicine
Email: Cara.East@BSWHealth.org
Research team
Merielle Boatman, MBA, BAAS
Research Manager
Merielle.Boatman@BSWHealth.org
Kyle Bass, MD
Clinical Research Coordinator II
Kyle.Bass@BSWHealth.org
Pamela Coker, RN, CCRC
Research Nurse
Pamela.Coker@BSWHealth.org
Poupak Moshayedi, RN, CCRC
Research Nurse
Poupak.Moshayedi@BSWHealth.org
JaKarsha Culton, RN, CCRC
Research Nurse
jaKarsha.Culton@BSWHealth.org
Aaron Mercado-Reza, MS, BA
Clinical Research Coordinator I
Aaron.MercadoReza@BSWHealth.org
Janet Jackson, BS HIM
Data Enrollment Analyst
Janet.Jackson@BSWHealth.org
Elizabeth Beene
Research Enrollment Analyst
Elizabeth.Beene@BSWHealth.org
LaTosha Williams
Regulatory Specialist
LaTosha.Williams@BSWHealth.org
Shanet Stefanos, BA
Research Enrollment Analyst
Recruitment and Marketing Specialist
Shanet.Stefanos@BSWHealth.org
Jackie Clark
Administrative Assistant I
Jackie.Clark@BSWHealth.org
Mary Jessie Guerra
Medical Assistant
MaryJessie.Guerra@BSWHealth.org
Natalia Feliz
Clinical Research Coordinator
Natalia.Feliz@BSWHealth.org
What it means to be a Blue Ribbon site
A commitment to excellence is a unifying principle that can inspire a team to go beyond just doing their jobs. While a culture of excellence includes ingredients like a shared vision, mastery of roles, accountability and collaboration, the key ingredients are pride and inspiration. Clinical research is a tough, often frustrating business that needs the inspiration to rise above mediocrity and deserves pride when excellence is achieved. Excellent sites exhibit the following characteristics:
- Experience
- Stability
- Quick study start-up
- Access to a large patient database
- Consistently meet or exceed enrollment commitments
- Generate high-quality data in a timely manner
About MAGI Blue Ribbon
MAGI is an organization that assists in streamlining clinical research by standardizing best practices for clinical research operations, business, and regulatory compliance. There are 10,000+ members represent clinical research sponsors, sites and CROs. MAGI is operated by First Clinical Research LLC, a company dedicated to advancing the practice of clinical research.
Contáctanos
Merielle Boatman
Phone: 214.820.2273
Merielle.Boatman@BSWHealth.org
Fax: 214.820.6236
Soltero Cardiovascular Research Center
621 N Hall St., Suite 530
Dallas, TX 75226